Frontlight ResearchEarly access
Not yet taking people in NetherlandsPhase 2/3
Repeat [18F]F-AraG PET scans in adults with lung cancer
Compares two close-together [18F]F-AraG PET scans in adults with lung cancer.
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)
- Status
- Not yet recruiting
- Phase
- Phase 2/3
- People taking part
- 7 people, planned
- Started
- 1 Oct 2025
- Planned end
- 1 Jul 2026
- Type of study
- Interventional
- Record updated
- 27 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with confirmed lung cancer who have at least one tumour of 2 cm (0.8 in) or larger. Each person has two close-together PET scans with [18F]F-AraG.
- Age
- Above 18 years
- Sex
- All sexes can join.
- Disease stage
- Lung cancer confirmed by tissue examination. At least 1 lesion of ≥2cm (0.8 in). Disease must be measurable by RECIST 1.1.
- Earlier treatment
- Cannot be on active immunomodulatory treatment. Cannot have needed systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medicines within 14 days of day 0.
Main reasons for not taking part
- Active immunomodulatory treatment
- Systemic corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medicines within 14 days of day 0
- Psychiatric or substance abuse disorders that would interfere with cooperation with the trial
- Pregnant or breastfeeding, or expecting to conceive during the trial
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Histologically confirmed lung cancer 2. At least 1 lesion with size of ≥2cm 3. Willing and able to provide written informed consent for the trial 4. Above 18 years of age on day of signing informed consent 5. Have measurable disease based on RECIST 1.1
Who cannot take part
- Patients on active immunomodulatory treatment 2. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. 3. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 4. Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsNot yet recruiting
About the trial
What the trial wants to find out
To measure the variability in tumor and organ uptake between two, closely obtained, [18F]F-AraG PET scans.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)
- Plain-language title
- Repeat [18F]F-AraG PET scans in adults with lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 27 January 2026